Eli Lilly To Acquire Centessa Pharmaceuticals For $38.00 In Cash Per Share Plus One Non-Transferrable Contingent Value Right
Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disordersAcquisition expands Lilly's neuroscience



























